4,412 reports of this reaction
1.4% of all DICLOFENAC SODIUM TOPICAL reports
#20 most reported adverse reaction
HEPATIC ENZYME INCREASED is the #20 most commonly reported adverse reaction for DICLOFENAC SODIUM TOPICAL, manufactured by Aurobindo Pharma Limited. There are 4,412 FDA adverse event reports linking DICLOFENAC SODIUM TOPICAL to HEPATIC ENZYME INCREASED. This represents approximately 1.4% of all 323,576 adverse event reports for this drug.
Patients taking DICLOFENAC SODIUM TOPICAL who experience hepatic enzyme increased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEPATIC ENZYME INCREASED is a less commonly reported adverse event for DICLOFENAC SODIUM TOPICAL, but still significant enough to appear in the safety profile.
In addition to hepatic enzyme increased, the following adverse reactions have been reported for DICLOFENAC SODIUM TOPICAL:
The following drugs have also been linked to hepatic enzyme increased in FDA adverse event reports:
HEPATIC ENZYME INCREASED has been reported as an adverse event in 4,412 FDA reports for DICLOFENAC SODIUM TOPICAL. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEPATIC ENZYME INCREASED accounts for approximately 1.4% of all adverse event reports for DICLOFENAC SODIUM TOPICAL, making it a notable side effect.
If you experience hepatic enzyme increased while taking DICLOFENAC SODIUM TOPICAL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.